Plain-English translation of NCT05289245 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a national registry study in China that gathers medical information from patients with cystic fibrosis—a rare genetic disease that affects the lungs and digestive system. Researchers want to understand how cystic fibrosis affects Chinese patients specifically, including how it's diagnosed, what treatments work best, and how patients are doing overall. By participating, you would be helping doctors learn more about this disease in your country.
Cystic fibrosis is relatively uncommon in Chinese populations, and very little is known about how it presents or progresses in Chinese patients compared to other groups. This study exists to fill that knowledge gap so that Chinese doctors can better diagnose, treat, and care for patients with this condition.
You likely qualify if…
You likely don't qualify if…
As a participant, you would share your medical information—including your diagnosis history, current symptoms, treatments you're receiving, genetic test results if available, and information about how the disease has affected your daily life and health. The study does not involve taking a new medication or undergoing experimental procedures. Instead, it focuses on collecting and analyzing information from your existing medical records and may involve completing questionnaires about your health and quality of life.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Sponsor
Peking Union Medical College Hospital
Enrollment target
~200 participants
Started
April 2022
Primary completion
October 2032
Last updated on clinicaltrials.gov in March 2022.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xinlun Tian, M.D.
Peking Union Medical College Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.